The short answer
Ozempic's FDA label starts everyone at 0.25 mg injected under the skin once weekly for four weeks, then increases to 0.5 mg once weekly. If more blood-sugar control is needed, the dose may go to 1 mg and then to 2 mg, with at least four weeks at each step. The maximum is 2 mg once weekly. The label is explicit that this escalation exists "to reduce the risk of gastrointestinal adverse reactions."
This page is reference, not instruction. Everything below describes what the FDA-approved label publishes. It is public fact, and you are entitled to read it. It is not a dosing plan for you. Your prescriber sets your dose — the starting dose, whether and when you step up, and where you stay. Do not adjust your dose yourself. Do not skip ahead to a higher dose. Do not double up after a missed dose. And do not split or stretch doses to make a pen last longer.
The published schedule
The current Ozempic label on DailyMed (revised May 2026) lays out one ladder. It is short, and it is worth reading in its actual shape rather than in a telehealth blog's paraphrase.
| Step | Dose (once weekly) | Minimum time at this step | What the label says it is for |
|---|---|---|---|
| 1 | 0.25 mg | 4 weeks | Treatment initiation. The label describes this as a starting dose, not a dose intended to control blood sugar. |
| 2 | 0.5 mg | At least 4 weeks before any increase | The first maintenance dose. Many people stay here. |
| 3 | 1 mg | At least 4 weeks before any increase | Used if additional glycemic control is needed. Also the maintenance dosage in the chronic-kidney-disease indication. |
| 4 | 2 mg | Maximum recommended dose | Used if additional control is still needed after at least 4 weeks at 1 mg. |
Two things people routinely get wrong. First, 0.5 mg, 1 mg and 2 mg are all maintenance doses. The ladder is not a staircase you are expected to climb to the top; it is a set of stopping points. Second, four weeks is a minimum, not a schedule. Nothing in the label obliges a prescriber to move you up on day 29.
A third detail surprises people: the label does not set a different dose for kidney or liver impairment — no dosage adjustment is recommended on that basis. What actually changes the plan is tolerance and glycemic response, and reading those is a clinical judgement, not an arithmetic one you make at home.
Why the ramp is slow — and why that is the whole point
Semaglutide slows how fast the stomach empties and acts on gut and brain signalling. That is a large part of how it works, and it is also exactly why it makes people nauseated. The gut adapts to the drug, but it adapts on its own timeline — roughly the timeline the four-week steps were built around. Going up faster does not produce faster results; it mostly produces vomiting, and vomiting is what gets people dehydrated, sent to urgent care, and off the drug for good.
The slow ramp is the single reason most people tolerate semaglutide at all. It is not caution theatre. If you want the mechanism in plain language, see how GLP-1 medications actually work, and our drug reference on semaglutide for the full profile.
What each step tends to feel like
These are patterns reported in trials and in clinic, not promises. Individual experience varies enormously, and "I felt nothing" is a completely normal outcome at any step.
| Dose | What people commonly report | What it does not mean |
|---|---|---|
| 0.25 mg | Mild early fullness, some nausea in the 24–72 hours after the shot, occasional burping or reflux. Some people feel nothing at all. | Feeling nothing is not a sign the drug "isn't working." This dose is not meant to do much yet. |
| 0.5 mg | Appetite suppression becomes noticeable for many. Nausea and constipation are the usual complaints. Symptoms often ease over 2–4 weeks at the same dose. | A rough first week here is not automatically a reason to abandon the step — but it is a reason to tell your prescriber. |
| 1 mg | Stronger effects and, for some, a return of nausea that had settled. Fatigue and constipation are common complaints at this step. | A return of side effects at a new step is expected biology, not a personal failure. |
| 2 mg | The ceiling dose. Side effects are dose-related, so this step is where tolerance problems most often force a rethink. | The maximum dose is not the "real" dose. Plenty of people never need it. |
Side effects at a step: the honest answer is usually "wait", and it is not your call
The most common real-world question is: I feel awful at this dose — do I push through or go back down? The honest answer is that in practice, prescribers most often hold you at the current step longer rather than pushing on, because gut adaptation is a matter of weeks and there is no clinical prize for reaching 2 mg quickly. Sometimes they step back down. Sometimes they stop.
All three of those are prescriber decisions, and none of them is yours to make alone. What you can do is come to the conversation with usable information: which day after your shot the symptoms peak, how many days they last, whether you are keeping fluids down, and whether anything is escalating rather than settling.
If you want a realistic timeline for when effects show up rather than a guess, our how-long-until-it-works tool gives the evidence-based ranges. For the side-effect profile in detail, see Ozempic and Wegovy side effects.
Missed doses
The label's instruction is narrow and specific: if a dose is missed, it may be administered within 5 days of the missed dose; if more than 5 days have passed, that dose is skipped and the next one is taken on the regular day. You do not double up to catch up. Doubling a weekly GLP-1 dose is a fast route to severe nausea and vomiting. If you are unsure where you are in the window, ask your pharmacist — they can answer this in thirty seconds.
The maintenance-dose question
"What is the maintenance dose of Ozempic?" has no single answer, and any page that gives you one is guessing. The label lists 0.5 mg, 1 mg or 2 mg as maintenance options, chosen on the basis of glycemic control. In the chronic-kidney-disease indication, the label describes 1 mg as the maintenance dosage, reached after at least four weeks at 0.5 mg.
Which one is yours depends on what your labs do, what side effects you have, and what your prescriber is treating. It is worth saying clearly, because a lot of internet advice implies otherwise: staying at 0.5 mg indefinitely is a legitimate, label-consistent outcome, not an unfinished treatment course.
It also matters what Ozempic is approved for. Ozempic is FDA-approved for glycemic control in type 2 diabetes, for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and established cardiovascular disease, and for reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney disease. Weight loss is not an approved indication for Ozempic — that is Wegovy, which uses the same molecule on a different, higher ladder topping out at 2.4 mg. The distinction is not pedantry: it drives what your insurer will and will not pay for. See Wegovy vs Ozempic.
Money, and the dangerous thing people do about it
The reason readers arrive at a dosage page is often financial, not clinical: they are trying to work out whether a pen can be stretched. So let us be direct about both halves of that.
Stretching or splitting doses to save money is a real practice and a genuinely risky one. It changes the dose you receive in ways nobody has characterised, it can break the titration logic entirely, and drawing from a pen with a separate syringe introduces contamination and dosing-error risk. If cost is the reason you are considering it, that is a conversation to have with your prescriber out loud — they have options you do not, including changing the dose formally, switching product, or writing for what your plan actually covers.
Manufacturer prices, checked 13 July 2026. Novo Nordisk's own NovoCare pages list a self-pay price of $199 per month for the first two monthly fills of the 0.25 mg or 0.5 mg pen for people new to the offer, available through 31 December 2026; after that, self-pay pricing is listed as $349 per month for 0.25 mg, 0.5 mg or 1 mg and $499 per month for 2 mg. For people with commercial insurance, the savings card is advertised as "pay as little as $25" a month for up to three months, subject to a stated maximum saving of $100 per month; people on Medicare, Medicaid or other government coverage are excluded from that card, and Novo Nordisk states it can modify or cancel the program at any time. These figures change — check NovoCare directly before you rely on any of them, including these.
Note what the pricing tiers do: the 2 mg dose costs more than the lower ones. That is worth knowing before you assume that higher is better.
On compounded semaglutide. Compounded semaglutide is not an FDA-approved drug. The FDA does not review compounded products for safety, effectiveness or quality, and nothing on this label — the ladder, the intervals, the safety data — applies to them. The FDA declared the semaglutide shortage resolved in February 2025, and with it the shortage-based exemption that had allowed mass compounding; since then the agency's position is that large-scale compounding of semaglutide is no longer permitted, with narrow exceptions for a documented individual clinical need.
The documented harm here is specifically a dosing harm. The FDA has issued an alert about dosing errors with compounded semaglutide supplied as a multiple-dose vial and a syringe rather than a metered pen: patients unused to self-injection, given syringes far larger than the prescribed volume, and instructions written in "units" rather than milligrams or millilitres, have administered many times the intended dose. In one case the FDA describes, the patient was themselves a health care provider, recalculated the dose in "units," and injected ten times the intended amount. The agency's reported consequences include severe nausea and vomiting, abdominal pain, fainting, headache, dehydration, gallstones and acute pancreatitis, with some patients seeking medical attention or being hospitalised. Compounded products also come in varying concentrations, so a "unit" does not mean the same thing from one vial to the next. We are not going to tell you to use or avoid a compounded product. But if you are handed a vial and a syringe, know that the unit-conversion step is exactly where people have been hurt, and that no pen-based titration table — including the one above — describes what is in that vial.
Disclosure: VidaBeacon may earn a commission from some links to care or products on this site. That never affects what we write, and nothing on this page is a recommendation to buy anything. We name no telehealth provider here on purpose.
Talk to your prescriber — and what to ask
Contact your prescriber, or seek urgent care, if you have:
- Vomiting you cannot stop, or an inability to keep fluids down
- Severe, persistent abdominal pain, especially pain that bores through to your back (a possible sign of pancreatitis)
- Signs of dehydration: dizziness on standing, very dark urine, not urinating
- Symptoms of low blood sugar, particularly if you also take insulin or a sulfonylurea
- Vision changes, or a rapidly worsening symptom of any kind
- A lump or swelling in your neck, hoarseness, or trouble swallowing (the label carries a boxed warning about thyroid C-cell tumours)
Questions worth writing down before your appointment:
- "What dose am I on, and what is the goal dose you have in mind for me?"
- "If I feel bad at this step, would you hold me here longer rather than step up?"
- "Are you treating my blood sugar, my cardiovascular risk, my kidneys — or my weight? Which product is right for that?"
- "My plan is denying this. What exactly did they cite, and will you file the appeal?"
If cost is the barrier, our cost and coverage estimator can help you work out what to ask your plan. Coverage rules are set by your specific plan, and no website — including this one — can tell you what yours says. Ask for the denial reason in writing, and give the plan an accurate account of your diagnosis and what you have already tried; appeals are won on the record, not on a better story. HealthCare.gov's appeals guidance sets out the two rights you have: an internal appeal, and then an independent external review. Both are real, and both are free to use.
Related reading: GLP-1 dosing schedules compared, GLP-1s and muscle loss, Mounjaro vs Ozempic, and our weight and metabolism hub.
